RAG-01 is named as an intervention in 2 current clinical trials in our China and Australia registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Ractigen Therapeutics. The most-studied condition is Non-muscle Invasive Bladder Cancer (NMIBC).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
NCT06351904 · ClinicalTrials.gov ↗ · Non-Muscle-Invasive Bladder Cancer (NMIBC)
|
Phase 1 | Recruiting | Ractigen Therapeutics | Australia |
|
A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).
NCT07777848 · ClinicalTrials.gov ↗ · Non-muscle Invasive Bladder Cancer (NMIBC)
|
Phase 2 | Not yet open | Ractigen Therapeutics | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Ractigen Therapeutics | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 1 | 0 |
| Clinical trials in Australia | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China and Australia registers name RAG-01 as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Ractigen Therapeutics. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RAG-01 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RAG-01 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RAG-01 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.